Mogamulizumab-kpkc (Poteligeo), a humanized monoclonal antibody that targets CCR4, provides a new treatment option for patients with MF and is the first FDA-approved therapy for SS.
Being able to identify which patients would respond to standard therapies allows for early adjustment in treatment and improves outcomes.
Findings from a previous study suggested that Q fever may significantly increase a person's risk of nHL.
Previous findings showed that patients obinutuzumab plus bendamustine prolonged progression-free survival, but data was immature at the time of analysis.
Dual expression of MYC and BCL2 was associated with worse survival among patients with GCB-like DLBCL, though this status was not associated with any outcomes among patients with ABC-like DLBCL.
Data support use of bendamustine for patients treated with several lines of therapy, but whether this drug should be used in the first line is open to question.
More studies are needed to determine the association between periodontal disease and non-Hodgkin lymphoma.
Thirty-month complete response is an accurate predictive endpoint for progression-free survival in follicular lymphoma clinical trials.
Non-Hodgkin lymphoma (NHL) is a group of cancers affecting cells called lymphocytes in the lymphatic system.
Obinutuzumab combined with bendamustine improved progression-free survival in rituximab-refractory indolent non-Hodgkin lymphoma (iNHL).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Ibrutinib in Chronic Lymphocytic Leukemia Deemed Not Cost-Effective by ICER Standards
- Albumin-to-Fibrinogen Ratio May Predict Poor Outcomes in Chronic Lymphocytic Leukemia
- In Search of the Right Sequence for Venetoclax in CLL
- Depression as a Side Effect: Exploring a Link Between Certain Cancer Treatments and Mental Health
- FDA Grants Accelerated Approval to Nivolumab for Small Cell Lung Cancer